[Translation from Japanese to English ] Currently, the intravenous-injection treatment for midazolam is undergoing cl...

Additional info

medical

Original text

「ポイント」・てんかん(けいれん)重積状態は, 乳幼児と高齢者に多い. ・原因は多様であり, 予後は, 基本的に原疾患に左右され, 治療に際しては複雑な要因が関与するので絶対的な方法はない. ・けいれん発作が長く続くほど止まりにくくなり, その後の脳の発達に影響する. ・わが国で2009年12月より静注用フェノバルビタール(ノーベルバール(R)), 2011年12月にフォスフェニトイン(ホストイン(R))が適応承認となったことは福音である.

Translation / English

[Point]: The Status Epilepticus (convulsive state) is frequently observed for the infants and the elderly. Since there is wide variety of causes, the prognosis depends on the primary disease so that there is no absolute medical treatment due to the complicated factors. If the developed convulsive seizer prolonged longer, it becomes hard to be stopped, and as a result, it may affect the brain development after then. It is the good news that two drugs, the Phenobarbital (Nobelbar®) since December 2009 and the fosphenytoin (Fostin®), have been put into the market as the approved drug labels.

Translation / English

<Point>
・ Status epilepticus is often seen in the infants and eldery.
・ Its cause is various, and the prognosis normally depends on the primary disease. Since complicated factors concern, there is no definite method of treatment for it.
・ Longer convulsive seizure continues, more difficult it will be to stop status epilepticus, and will affect the subsequent growth of the brain.
・ It is a good news that the approval of the indication of intravenous phenobarbital （Nobelbar(R)） since Dec 2009 and fosphenytoin (Fostoin(R)) in December 2011.

naoko_horigome330- almost 11 years ago
申し訳ありません。訳抜けがありました。文章の最後、「2011」の直後に「in our country」を挿入してください。よろしくお願いします。

takutim- almost 11 years ago
ありがとうございます！こちらで挿入致します。

Original text

・現在, ミダゾラムの静注療法はわが国で治験中(アルフレッサファーマ社)である. EUでは2011年9月に口腔内投与が認められた. わが国でも早急な開発・承認が待ち望まれる. 「はじめに」てんかん重積状態(けいれん重積〕は, 「発作がある程度の長さ以上に続くか, または短い発作でも反復しその間意識の回復がないもの」とILAE(International League Against Epilepsy)(1981)で定義されている.

Translation / English

Currently, the intravenous-injection treatment for midazolam is undergoing clinical trial in our country. In EU, its oral administration was approved in September, 2011. Our country has been expecting its quick development and approval. Firstly, according to ILAE (International League Against Epilepsy) (1981), status epilepticus (status convulsions) is defined as convulsions that persist longer than a certain period, or short convulsions that repeat themselves with no recovery from unconsciousness during convulsions.

Translation / English

Currently, intravenous injection treatment by midazolam is being experimented by Affesa Pharma, in our country. In Eurpoean Union, injection into oral cavity was authorized in September 2011. It is hoped that it will be developed and authorized urgently in our country. At first, status epilepticus is the condition where fit continues longer than certain time, or even if the fit is short , he or she does not come back to be conscious while the fit repeats. It is defined in International League Against Elilepsy 1981.

Translation / English

・At present time, intravenous-injection treatment of midazolam is on clinical research in our country (Alfresa Pharma Corporation). In EU, its buccal administration is approved in September 2011. Urgent development and approval is also desired in our country.

[Introduction]
Status epilepticus is defined as “the condition in which a seizure continues more than some length of time or a short time seizure which repeats and the patient does not recover his/her consciousness during that time” by ILAE(International League Against Epilepsy)(1981).

Translation / English

Currently, the intravenous-injection treatment using the midazolam is on going in Japan as the investigational treatment (Alfressa Pharma Corp.). In September 2011, EU has approved the buccal administration of the midazolam. It is looking forward to the quick development and approval of the drug label in Japan. “Introduction”: Status epilepticus is defined by ILAE(International League Against Epilepsy)(1981) as “one continuous, unremitting seizure lasting longer than certain period of time or recurrent seizure without regaing consciousness between seizures”